Cargando…

Changes in Glycemic Control and Body Weight After Initiation of Dapagliflozin or Basal Insulin Supported Oral Therapy in Type 2 Diabetes: A Primary Care Database Study

BACKGROUND: The aim was to compare changes in HbA1c and body weight after initiation of dapagliflozin or basal insulin supported oral therapy (BOT) in type 2 diabetes patients in primary care practices. METHODS: Patients from 983 primary care practices who started dapagliflozin or BOT between Decemb...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kostev, Karel, Pscherer, Stefan, Rist, Roland, Busch, Stefan, Scheerer, Markus F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505432/ https://www.ncbi.nlm.nih.gov/pubmed/28300454 http://dx.doi.org/10.1177/1932296816688011

Ejemplares similares

Changes in HbA1c, body weight, and systolic blood pressure in type 2 diabetes patients initiating dapagliflozin therapy: a primary care database study
por: Scheerer, Markus F, et al.
Publicado: (2016)

Glycemic control after initiating basal insulin therapy in patients with type 2 diabetes: a primary care database analysis
por: Kostev, Karel, et al.
Publicado: (2015)

Effectiveness and tolerability of treatment intensification to basal–bolus therapy in patients with type 2 diabetes on previous basal insulin-supported oral therapy with insulin glargine or supplementary insulin therapy with insulin glulisine: the PARTNER observational study
por: Pfohl, Martin, et al.
Publicado: (2015)

Cost comparison of insulin glargine with insulin detemir in a basal-bolus regime with mealtime insulin aspart in type 2 diabetes in Germany
por: Pscherer, Stefan, et al.
Publicado: (2010)

Adverse Changes in HbA1c, Body Weight and Insulin Use in People with Type 1 Diabetes Mellitus Following Dapagliflozin Discontinuation in the DEPICT Clinical Trial Programme
por: Gordon, Jason, et al.
Publicado: (2020)

Fracture risk in patients with type 2 diabetes under different antidiabetic treatment regimens: a retrospective database analysis in primary care
por: Pscherer, S, et al.
Publicado: (2016)

Dapagliflozin effects on haematocrit, red blood cell count and reticulocytes in insulin-treated patients with type 2 diabetes
por: Aberle, Jens, et al.
Publicado: (2020)

THU244 Clinical Factors Affecting Dapagliflozin Response For Glycemic Control And Body Weight Reduction: Post-hoc Analysis Of BEYOND Study
por: Jeung Ahn, Kyu, et al.
Publicado: (2023)

Risk of hypoglycaemia in type 2 diabetes patients under different insulin regimens: a primary care database analysis
por: Kostev, Karel, et al.
Publicado: (2015)

Effect of Renin-Angiotensin System Blockade on Insulin Resistance and Inflammatory Parameters in Patients With Impaired Glucose Tolerance
por: Pscherer, Stefan, et al.
Publicado: (2010)

Effect of Dapagliflozin on Glycemic Variability in Patients with Type 2 Diabetes under Insulin Glargine Combined with Other Oral Hypoglycemic Drugs
por: Luo, Menghui, et al.
Publicado: (2020)

A retrospective database analysis of insulin use patterns in insulin-naïve patients with type 2 diabetes initiating basal insulin or mixtures
por: Bonafede, Machaon MK, et al.
Publicado: (2010)

The role of sulfonylurea plus basal insulin on glycemic variability compared to basal bolus regime in T2D patients
por: Freire, Paula Vieira, et al.
Publicado: (2015)

FRI638 Glycemic And Cost Outcomes In Hispanic/Latino People With Type 2 Diabetes Initiating Dulaglutide Or Basal Insulin In The US
por: Hoog, Meredith, et al.
Publicado: (2023)

Effect of dapagliflozin on 24-hour glycemic variables in Japanese patients with type 2 diabetes mellitus receiving basal insulin supported oral therapy (DBOT): a multicenter, randomized, open-label, parallel-group study
por: Kudo, Akihiro, et al.
Publicado: (2023)

Relevance of the Glycemic Index and Glycemic Load for Body Weight, Diabetes, and Cardiovascular Disease
por: Vega-López, Sonia, et al.
Publicado: (2018)

Glycated Hemoglobin, Body Weight and Blood Pressure in Type 2 Diabetes Patients Initiating Dapagliflozin Treatment in Primary Care: A Retrospective Study
por: Wilding, John, et al.
Publicado: (2016)

Influence of Dapagliflozin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes Mellitus
por: Li, Feng-fei, et al.
Publicado: (2016)

Dapagliflozin Does Not Modulate Atherosclerosis in Mice with Insulin Resistance
por: Taberner-Cortés, Alida, et al.
Publicado: (2020)

Effects of Dapagliflozin Adjunct to Insulin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes: A Randomized, Controlled, Open-Labeled Trial
por: Jiang, Lan-lan, et al.
Publicado: (2021)

Benefit/risk profile of dapagliflozin 5 mg in the DEPICT‐1 and ‐2 trials in individuals with type 1 diabetes and body mass index ≥27 kg/m(2)
por: Mathieu, Chantal, et al.
Publicado: (2020)

Glycemic Control Following GLP-1 RA or Basal Insulin Initiation in Real-World Practice: A Retrospective, Observational, Longitudinal Cohort Study
por: Peng, Xuejun Victor, et al.
Publicado: (2020)

Glycemic control and adherence to basal insulin therapy in Taiwanese patients with type 2 diabetes mellitus
por: Chien, Ming‐Nan, et al.
Publicado: (2016)

Reconsidering the Basal Proportion of Insulin Dose: Glycemic and Microvascular Outcomes in Type 1 Diabetes Mellitus
por: Pozos-Varela, Francisco Javier, et al.
Publicado: (2021)

Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes: A randomized, crossover study
por: Rosenstock, Julio, et al.
Publicado: (2013)

Relationship between basal sodium intake and the effects of dapagliflozin in albuminuric diabetic kidney disease
por: Kinguchi, Sho, et al.
Publicado: (2021)

Replacement of neutral protamine Hagedorn insulin with the long‐acting insulin analogue, detemir, improves glycemic control without weight gain in basal–bolus insulin therapy in Japanese patients with type 1 diabetes
por: Hayakawa, Taro, et al.
Publicado: (2011)

Comparison of Glycemic Variability and Hypoglycemic Events in Hospitalized Older Adults Treated with Basal Insulin plus Vildagliptin and Basal–Bolus Insulin Regimen: A Prospective Randomized Study
por: Batule, Sol, et al.
Publicado: (2022)

A Retrospective Database Study of Liraglutide Persistence Associated with Glycemic and Body Weight Control in Patients with Type 2 Diabetes
por: Melzer-Cohen, Cheli, et al.
Publicado: (2019)

Effects of Dapagliflozin and Sitagliptin on Insulin Resistant and Body Fat Distribution in Newly Diagnosed Type 2 Diabetic Patients
por: Sun, Yue, et al.
Publicado: (2020)

Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes
por: Jang, Han Na, et al.
Publicado: (2019)

The importance of the initial period of basal insulin titration in people with diabetes
por: Khunti, Kamlesh, et al.
Publicado: (2020)

Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial
por: Persson, Frederik, et al.
Publicado: (2021)

HbA1c target achievement in the elderly: results of the Titration and Optimization trial for initiation of insulin glargine 100 U/mL in patients with type 2 diabetes poorly controlled on oral antidiabetic drugs
por: Fritsche, Andreas, et al.
Publicado: (2019)

Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control
por: Kohan, Donald E, et al.
Publicado: (2014)

Effıcacy and safety of dapagliflozin on diabetic patients receiving high-doses of insulin
por: Sertbas, Meltem, et al.
Publicado: (2019)

Dapagliflozin's effect on serum homocysteine in patients with hypertension complicated with insulin resistance
por: Yu, Xiaoqian, et al.
Publicado: (2023)

Association of glucose-lowering drugs with incident stroke and transient ischaemic attacks in primary care patients with type 2 diabetes: disease analyzer database
por: Rathmann, Wolfgang, et al.
Publicado: (2022)

SAT-LB025 Analysis of Benefit/Risk in the Subgroup of Patients with BMI of >=27 Kg/m(2) in the Dapagliflozin DEPICT-1 and -2 Trials in Type 1 Diabetes
por: Mathieu, Chantal, et al.
Publicado: (2019)

Effect of Dapagliflozin as an Add-on Therapy to Insulin on the Glycemic Variability in Subjects with Type 2 Diabetes Mellitus (DIVE): A Multicenter, Placebo-Controlled, Double-Blind, Randomized Study
por: Lee, Seung-Hwan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_u17596mednmn4otjgl2u5r975c